Lucid Diagnostics (LUCD), a majority-owned subsidiary of PAVmed (PAVM), announced that it performed a record number of commercial EsoGuard Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter. Lucid also reported that it held a productive meeting with CMS Medicare Administrative Contractor Palmetto GBA’s Molecular Diagnostics Program.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUCD:
Questions or Comments about the article? Write to editor@tipranks.com